Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis.

IF 3.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Expert Review of Clinical Pharmacology Pub Date : 2025-01-16 DOI:10.1080/17512433.2025.2450254

Jay Tewari, Khalid Ahmad Qidwai, Ajoy Tewari, Savneet Kaur, Vineeta Tewari, Anuj Maheshwari

{"title":"Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis.","authors":"Jay Tewari, Khalid Ahmad Qidwai, Ajoy Tewari, Savneet Kaur, Vineeta Tewari, Anuj Maheshwari","doi":"10.1080/17512433.2025.2450254","DOIUrl":null,"url":null,"abstract":"Introduction: Retatrutide is a novel triple hormone receptor agonist which has shown great promise in tackling obesity in preliminary trials. We did this systematic review and meta-analysis to pool the results of all available trials and ascertain its safety and efficacy in the treatment of obesity.Material and methods: A literature search was conducted in PubMed, Cochrane Central and Embase using appropriate search terms and randomized control trials (RCTs) were identified which reported the safety and efficacy of retatrutide. Data was pooled using mean differences for continuous variables and risk ratios for the safety profile in RStudio.Results: After the initial search four RCTs were included in the analysis which compared the safety and efficacy of retatrutide versus placebo. Retatrutide showed a dose dependent relationship with the 12 mg dose causing the maximum reductions across all the outcomes considered. The safety profile of retatrutide was found to be comparable to the control group.Conclusion: In conclusion our analysis found retatrutide to be clinically and statistically better than placebo in the various studies outcomes. We eagerly await the conduction of further trials for more robust and substantial results.Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD42024566153.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-16"},"PeriodicalIF":3.6000,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17512433.2025.2450254","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Retatrutide is a novel triple hormone receptor agonist which has shown great promise in tackling obesity in preliminary trials. We did this systematic review and meta-analysis to pool the results of all available trials and ascertain its safety and efficacy in the treatment of obesity.

Material and methods: A literature search was conducted in PubMed, Cochrane Central and Embase using appropriate search terms and randomized control trials (RCTs) were identified which reported the safety and efficacy of retatrutide. Data was pooled using mean differences for continuous variables and risk ratios for the safety profile in RStudio.

Results: After the initial search four RCTs were included in the analysis which compared the safety and efficacy of retatrutide versus placebo. Retatrutide showed a dose dependent relationship with the 12 mg dose causing the maximum reductions across all the outcomes considered. The safety profile of retatrutide was found to be comparable to the control group.

Conclusion: In conclusion our analysis found retatrutide to be clinically and statistically better than placebo in the various studies outcomes. We eagerly await the conduction of further trials for more robust and substantial results.

Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD42024566153.

查看原文本刊更多论文

三重激素受体激动剂利特鲁肽治疗肥胖的有效性和安全性：系统回顾和荟萃分析。

利特鲁肽是一种新型的三重激素受体激动剂，在治疗肥胖症的初步试验中显示出很大的希望。我们进行了系统回顾和荟萃分析，汇总了所有可用试验的结果，以确定其治疗肥胖的安全性和有效性。材料和方法：在PubMed、Cochrane Central和Embase中使用合适的检索词进行文献检索，并确定了报告利特鲁肽安全性和有效性的随机对照试验（rct）。使用RStudio中连续变量的平均差异和安全概况的风险比汇总数据。结果：在最初的搜索之后，四项随机对照试验被纳入分析，比较了利特鲁肽与安慰剂的安全性和有效性。利特鲁肽显示出剂量依赖关系，在所有考虑的结果中，12mg剂量导致最大的减少。利特鲁肽的安全性与对照组相当。结论：总之，我们的分析发现利特鲁肽在临床和统计学上优于安慰剂的各种研究结果。我们急切地等待进一步的试验，以获得更有力和实质性的结果。协议注册：www.crd.york.ac.uk/prospero标识为CRD42024566153。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Clinical Pharmacology PHARMACOLOGY & PHARMACY-

CiteScore

7.30

自引率

2.30%

发文量

127

期刊介绍： Advances in drug development technologies are yielding innovative new therapies, from potentially lifesaving medicines to lifestyle products. In recent years, however, the cost of developing new drugs has soared, and concerns over drug resistance and pharmacoeconomics have come to the fore. Adverse reactions experienced at the clinical trial level serve as a constant reminder of the importance of rigorous safety and toxicity testing. Furthermore the advent of pharmacogenomics and ‘individualized’ approaches to therapy will demand a fresh approach to drug evaluation and healthcare delivery. Clinical Pharmacology provides an essential role in integrating the expertise of all of the specialists and players who are active in meeting such challenges in modern biomedical practice.